Amarin posts Q2 2026 results as international partner sales grow, US expenses fall
Amarin said global in-market demand for VASCEPA/VAZKEPA rose 59% year over year while operating expenses excluding restructuring dropped 38%, with cash at $314.6 million.
SEC filing